1 completed, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow CSL689: new trials by email Literature Review of CSL689 trials Research Report on CSL689
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors CSL689, Eptacog alfa (activated) - Hemophilia A With Inhibitors, Hemophilia B With Inhibitors | Phase 2 / Phase 3 | Terminated | CSL Behring | 25 | 2015-07-23 | 2019-08-28 |
| Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency Eptacog alfa (activated) or pdFVII, CSL689 - Congenital Coagulation Factor VII Deficiency | Phase 1 | Completed | CSL Behring | 9 | 2015-07-01 | 2017-04-26 |
CSL Behring (2)
Georgia (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Norway (1) · Russia (1) · South Africa (1) · Spain (1) · Thailand (1) · Ukraine (1) · United Kingdom (1)
Alex Veldman (1)
2014 (1)